Results 191 to 200 of about 57,433,167 (306)
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Expression of Concern: Toll-Like Receptor 2 Targeted Rectification of Impaired CD8+ T Cell Functions in Experimental Leishmania donovani Infection Reinstates Host Protection. [PDF]
PLOS One Editors.
europepmc +1 more source
Correction: Automated self-service cohort selection for large-scale population sciences and observational research: The California Teachers Study researcher platform. [PDF]
PLOS One Staff.
europepmc +1 more source
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen +9 more
wiley +1 more source
Being There: Danish Nurses' Lived Experiences of Companionship With Families in Home-Based Paediatric Palliative Care in Regional Settings. [PDF]
Alm A, Beck M.
europepmc +1 more source
Correction: Point-of-care laboratory of pathogen diagnosis in Rural Senegal. [PDF]
PLOS Neglected Tropical Diseases Editors.
europepmc +1 more source
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
Molecular cancer prevention: Intercepting disease
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco +2 more
wiley +1 more source

